Acute myeloid leukemia targets for bispecific antibodies.
Despite substantial gains in our understanding of the genomics of acute myelogenous leukemia (AML), patient survival remains unsatisfactory especially among the older age group. T cell-based therapy of lymphoblastic leukemia is rapidly advancing; however, its application in AML is still lagging behind. Bispecific antibodies can redirect polyclonal effector cells to engage chosen targets on leukemia blasts. When the effector cells are natural-killer cells, both antibody-dependent and antibody-independent mechanisms could be exploited. When the effectors are T cells, direct tumor cytotoxicity can be engaged followed by a potential vaccination effect. In this review, we summarize the AML-associated tumor targets and the bispecific antibodies that have been studied. The potentials and limitations of each of these systems will be discussed.
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
S S
SS
Hoseini
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
N K
NK
Cheung
D018033:Antibodies, Bispecific / Q000627:therapeutic use*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D063268:Sialic Acid Binding Ig-like Lectin 3 / Q000235:genetics*; D014407:Tumor Cells, Cultured
D018033:Antibodies, Bispecific; D063268:Sialic Acid Binding Ig-like Lectin 3